Table 1 Demographic data of the studied groups
Cardiotoxicity | Non-cardiotoxicity | Test | p. value | ||
|---|---|---|---|---|---|
Stage | II (%) | 8 (44.4%) | 20 (41.7%) | X2: 0.041 | 0.839 |
III (%) | 10 (55.6%) | 28 (58.3%) | |||
ER (%) | 17 (94.4%) | 45 (93.8%) | X2: 0.011 | 0.916 | |
PR (%) | 11 (61.1%) | 34 (70.8%) | X2: 0.570 | 0.450 | |
RTH (%) | 16 (88.9%) | 41 (85.4%) | X2: 0.134 | 0.714 | |
HTN (%) | 4 (22.2%) | 17 (35.4%) | X2: 1.051 | 0.305 | |
DM (%) | 8 (44.4%) | 13 (27.1%) | X2:1.819 | 0.177 | |
Dyslipidemia (%) | 7 (38.9%) | 16 (33.3%) | X2:0.178 | 0.673 | |
Age | Mean ± S. D | 55.22 ± 5.76 | 44.13 ± 8.28 | T: 5.223 | 0.001* |
KI 67 | Mean ± S. D | 17.06 ± 7.02 | 17.31 ± 8.86 | T: 0.111 | 0.912 |
Dose | Mean ± S. D | 375.56 ± 36.66 | 363.33 ± 36.75 | T: 1.204 | 0.233 |